Navigation Links
Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009
Date:11/5/2009

CARLSBAD, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenues of $50.8 million for the third quarter of 2009, which includes a $4.4 million benefit from changes in accounting estimates resulting primarily from strong cash collections related to prior period revenue. Third quarter revenue increased 58% over revenue of $32.1 million for the comparable period in 2008, which included a $2.5 million benefit from changes in accounting estimates.

"Our performance in the third quarter was the product of exceptional execution, reflected by the increase in sales and new customer acquisitions, even during what is typically the slower summer vacation season," said Tina S. Nova, Ph.D., President and CEO of Genoptix. "By the end of September we were servicing approximately 1,300 community physicians across the country and managing more than 14,700 patient cases, an increase of approximately 45% from the number of cases managed during the same period in 2008."

Gross profit for the third quarter of 2009 was $32.4 million, or 64% of revenues, up from $19.8 million, or 62% of revenues, for the third quarter of 2008. Operating income for the third quarter of 2009 was $16.4 million, or 32% of revenues, compared to operating income of $8.6 million, or 27% of revenues, for the same period in 2008.

Net income was $9.5 million for the third quarter of 2009, or $0.53 diluted earnings per share (EPS), based on 18.0 million weighted average common shares outstanding and a tax rate of 43%. This compares to net income of $15.4 million for the third quarter of 2008, or EPS of $0.87, based on 17.8 million weighted average common shares outstanding, which would have been reduced by $0.57 if taxed at the comparable rate of 43%.

As of September 30, 2009, the Company's total cash, cash equivalents and investment securities were $141.9 million. Cash generated from operations was $14.0 million for the third quarter of 2009, with days sales outstanding of 51 days, as compared to 56 days at the end of the third quarter of 2008.

2009 Year-To-Date Performance

Revenues for the first nine months of 2009 totaled $135.3 million, including a $6.4 million benefit from changes in accounting estimates resulting primarily from strong cash collections related to revenue from prior years. This is an increase of 65% over revenues of $82.2 million for the comparable period in 2008, which included a $2.2 million benefit from changes in accounting estimates.

Gross profit for the first nine months of 2009 was $84.7 million, or 63% of revenues, up from $49.5 million, or 60% of revenues, for the first nine months of 2008. Operating income for the first nine months of 2009 was $39.9 million, or 30% of revenues, compared to operating income of $17.9 million, or 22% of revenues, for the same period in 2008.

Net income was $23.3 million for the first nine months of 2009, or EPS of $1.30, based on 17.9 million weighted average common shares outstanding and a tax rate of 44%. This compares to net income of $26.0 million for the first nine months of 2008, or EPS of $1.48, which would have been reduced by $0.84 if taxed at the comparable rate of 44%.

For the first nine months of 2009, cash generated from operations was $33.6 million, while purchases of capital equipment for the same period totaled $3.2 million. Bad debt expense for the first nine months of 2009 was 2% of revenue, as compared to 3% for the same period in 2008.

"It was another quarter of solid performance as we continued to fine-tune our operations and drive new business while maintaining our signature high-quality service offering," said Sam Riccitelli, Genoptix EVP and COO. "We made great progress on our hiring initiatives, ending the third quarter with 34 hematopathologists on staff with our Cartesian Medical Group, and 67 sales representatives in the field. The outstanding productivity of these groups has allowed us to revise our hiring plan through the close of 2009, which we now expect to end with the 34 physicians currently on staff, adding more at the start of 2010. Our sales team is expected to expand to approximately 85 field representatives by the end of the year, with additional sales staff to come as the new year begins."

Performance Outlook

Recognizing the strength of our collection efforts and financial results in the third quarter, Genoptix expects revenues for the full-year 2009 of approximately $180 million with full-year gross margins of approximately 60%.

Operating margins for 2009 are expected to be in the mid- to high-twentieth percentile, with net income of approximately $29 million, up from prior estimates of approximately $25 million. Diluted EPS for the full-year 2009 is now expected to be approximately $1.60, increasing from a prior range of $1.40 to $1.45, on about 18.0 million shares. This assumes a tax rate of approximately 44%, down from initial estimations of 45%.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company projects capital expenditures of $8.5 million for the full-year 2009, which includes approximately $4.5 million in maintenance capital. A planned laboratory expansion beginning this quarter is now expected to cost approximately $9.5 million, with approximately $4 million to be spent in 2009 and the remainder in the first half of 2010.

For 2010, revenues are expected to grow to approximately $235 million. The Company intends to provide more detailed guidance in February when reporting results for the fourth quarter and full-year 2009.

Conference Call Information

A conference call will take place on Thursday, November 5, 2009, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management. To access the live conference call via phone, dial 866-318-8620 in the U.S. or Canada and 617-399-5139 for international callers. Please specify to the operator that you would like to join the "Genoptix Third Quarter 2009 Earnings Conference Call." The participant code for the call is 65066785. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, November 12, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 62495576.

The conference call will also be webcast live on the "Investors" section of the Genoptix website at www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Thursday, December 3, 2009.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the Company's ability to provide high quality services and facilitate personalized medicine, the success of the Company's business model, improving case volumes, increasing revenues, customer adoption and growth, the Company's capacity to manage and support future growth and ability to expand its business, hire additional personnel and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects and ability to capture additional market share in the U.S., estimated effective tax rates and the Company's financial guidance for 2009 and 2010. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, financial risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

[Financial tables follow]

                                     GENOPTIX, INC.
                    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                       (unaudited)
                         (in thousands, except per share data)

                                    Three Months Ended       Nine Months Ended
                                       September 30,           September 30,
                                    ------------------       -----------------
                                     2009        2008         2009       2008
                                     ----        ----         ----       ----
    Revenues                      $50,807     $32,087     $135,294    $82,210
    Cost of revenues               18,402      12,282       50,603     32,663
                                   ------      ------       ------     ------
    Gross profit                   32,405      19,805       84,691     49,547
    Operating expenses:
      Sales and marketing           8,217       5,098       22,538     14,529
      General and administrative    7,287       5,786       21,168     16,091
      Research and development        522         333        1,049      1,003
                                      ---         ---        -----      -----
    Total operating expenses       16,026      11,217       44,755     31,623
                                   ------      ------       ------     ------
    Income from operations         16,379       8,588       39,936     17,924
    Interest and other income         334         650        1,268      2,302
                                      ---         ---        -----      -----
    Income before income taxes     16,713       9,238       41,204     20,226
    Income tax expense (benefit)    7,251      (6,190)      17,926     (5,780)
                                    -----      -------      ------     -------
    Net income                     $9,462     $15,428      $23,278    $26,006
                                   ------     -------      -------    -------

    Net income per share:
      Basic                         $0.55       $0.93        $1.38      $1.59
                                    -----       -----        -----      -----
      Diluted                       $0.53       $0.87        $1.30      $1.48
                                    -----       -----        -----      -----
    Shares used to compute net
     income per share:
      Basic                        17,089      16,535       16,909     16,336
                                   ------      ------       ------     ------
      Diluted                      17,965      17,754       17,892     17,616
                                   ------      ------       ------     ------
                                   GENOPTIX, INC.
                        CONDENSED CONSOLIDATED BALANCE SHEETS
                                   (in thousands)

                                               September 30,  December 31,
                                                   2009          2008
                                                   ----          ----
                                                (unaudited)
    Assets
    Current assets:
      Cash and cash equivalents                      $19,865       $38,108
      Short-term investment securities               117,922        64,830
      Accounts receivable, net                        23,529        15,604
      Deferred tax asset                               4,735         4,707
      Other current assets                             2,754         2,179
                                                       -----         -----
    Total current assets                             168,805       125,428
    Property and equipment, net                       12,759        12,189
    Long-term investment security                      3,883         3,775
    Long-term deferred tax asset                       2,347         2,510
    Restricted cash                                      270           360
    Other long-term assets                               350           183
                                                         ---           ---
    Total assets                                    $188,414      $144,445
                                                    --------      --------

    Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable and accrued expenses           $9,509        $6,580
      Accrued compensation                             7,558         3,006
      Income tax payable                                  95             -
      Deferred revenues                                1,119           365
      Deferred rent                                      301           241
                                                         ---           ---
    Total current liabilities                         18,582        10,192
    Long-term deferred rent                            1,766         1,955
    Other long-term liabilities                          300            79

    Stockholders' equity:
      Preferred stock                                      -             -
      Common stock                                        17            17
      Additional paid-in capital                     155,476       143,616
      Treasury stock                                     (11)            -
      Accumulated other comprehensive loss              (354)         (774)
      Accumulated earnings (deficit)                  12,638       (10,640)
                                                      ------       -------
    Total stockholders' equity                       167,766       132,219
                                                     -------       -------
    Total liabilities and stockholders' equity      $188,414      $144,445
                                                    --------      --------
                                     GENOPTIX, INC.
                     CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                       (unaudited)
                                     (in thousands)

                                                          Nine Months Ended
                                                            September 30,
                                                            -------------
                                                         2009           2008
                                                         ----           ----
    Operating activities:
      Net income                                      $23,278        $26,006
      Adjustments to reconcile net income to net
       cash provided by operating activities:
        Depreciation and amortization                   2,583            878
        Provision for doubtful accounts                 2,240          2,280
        Stock-based compensation expense                7,306          5,156
        Excess tax benefits from stock-based
         compensation awards                           (3,403)          (118)
        Amortization of premium (discount) on
         investment securities, net                       458           (163)
        Deferred taxes                                    (29)        (9,519)
        Realized loss on sale of investment                 -             66
        Loss (gain) on sale of property and equipment       6            (10)
      Changes in operating assets and liabilities:
        Accounts receivable                           (10,165)        (9,629)
        Other current and long-term assets               (713)           (50)
        Accounts payable and accrued expenses           2,922          3,075
        Accrued compensation                            4,552          2,443
        Income taxes                                    3,756          2,897
        Deferred revenues                                 754            (37)
        Deferred rent                                      43            149
                                                           --            ---
    Net cash provided by operating activities          33,588         23,424
                                                       ------         ------

    Investing activities:
      Purchase of property and equipment               (3,240)        (6,961)
      Proceeds from sales of property and equipment         -             21
      Purchase of investment securities              (120,508)      (103,605)
      Proceeds from sales and maturities of
       investment securities                           67,434         58,100
      Purchase of intangibles                            (150)             -
      Change in restricted cash                            90           (360)
                                                           --           ----
    Net cash used in investing activities             (56,374)       (52,805)
                                                      -------        -------

    Financing activities:
      Proceeds from issuance of common stock, net       1,151          1,177
      Excess tax benefits from stock-based
       compensation awards                              3,403            118
      Costs paid in connection with public offerings        -           (764)
      Repurchase of common stock                          (11)             -
      Proceeds from exercise of warrants                    -             35
                                                          ---             --
    Net cash provided by financing activities           4,543            566
                                                        -----            ---
    Net decrease in cash and cash equivalents         (18,243)       (28,815)
    Cash and cash equivalents at beginning of
     period                                            38,108         50,624
                                                       ------         ------
    Cash and cash equivalents at end of period        $19,865        $21,809
                                                      -------        -------

    Supplemental information:
    Income taxes paid                                 $14,222           $842
                                                      -------           ----
    Interest paid                                          $-             $5
                                                           --             --

    Non-cash investing and financing activities:
    Unrealized gain on investment securities, net        $584         $1,342
                                                         ----         ------
    Capitalized tenant improvement allowance               $-         $1,285
                                                           --         ------
    Change in accrued purchases of property and
     equipment                                            $69           $248
                                                          ---           ----

SOURCE Genoptix, Inc.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine technology :

1. Genoptix, Inc. Announces Availability of MPL W515 L/K Mutation Analysis for MPD at 49th Annual American Society of Hematology (ASH) Meeting
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. Spherix Reports Second Quarter Earnings
4. Tapestry Reports Second Quarter 2007 Results
5. Callisto Reports on Second-Quarter 2007 Milestones
6. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
7. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
8. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
9. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
10. Biopure Reports on Meeting with the FDA
11. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Automation is ... laboratory due to the growing demands for productivity in ... contemporary automated systems are already adept of a wide ... tedious and manual labor. Instrumentation continues to evolve, and ... conceivable just a few years ago. Originally used mostly ...
(Date:4/28/2016)... Research and Markets has announced the addition ... report to their offering.      (Logo: ... plastic surgery products market is expected to grow at ... ,The growing adoption of laser in aesthetics is another ... Lasers are used to treat a broad range of ...
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System ... Medical Education (ACGME) that it has received accreditation for its residency program on ... residency programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This ...
(Date:4/29/2016)... ... , ... Our bodies are bombarded daily by environmental and lifestyle factors that ... is to adopt a more healthful diet, but too many people think that food ... Nutritionist and the creator of the Newport Beach Cleanse and 14-Day Eating Plan, disagrees ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... ... 2016 , ... The White House announced efforts yesterday to ... about their loan terms and accounts, and more protections for borrowers. The announcement ... private loans, has reached $1.3 trillion, with 43 million Americans holding student loans ...
(Date:4/29/2016)... ... ... Coast Dental Fort Stewart is celebrating its grand opening with an open ... Mall at 112 Vilseck Road in Fort Stewart. There will be refreshments, giveaways, and ... the opportunity to meet general dentists Thomas Richards, DDS, and Josh Faulk, DMD, and ...
Breaking Medicine News(10 mins):